Gelion Plc engages in the manufacture of batteries and accumulators. The company is headquartered in Alexandria, New South Wales and currently employs 42 full-time employees. The company went IPO on 2021-11-30. The company conducts research and development in battery system and associated industrial design and manufacturing. The firm is engaged in the development of two battery chemistries-Lithium-Sulfur (Li-S) and Zinc hybrid cell technologies. Its lithium-sulfur and zinc-based storage solutions are designed to be alternatives to lithium-ion and lead-acid battery technologies. The batteries provide energy storage solution (ESS) for applications including stand-alone power system, commercial and industrial, utility scale stationary ESS, and reserve power (uninterrupted power supply, telecom). The firm is also focused on sulfur technology with lithium metal anode for drone and unmanned aerial vehicles (UAV), electric vehicles (EV), e-heavy vehicles and stationary storage.
최신 재무제표(Form-10K)에 따르면, Novelstem International Corp의 총 자산은 $0이며, 순손실입니다.
GELNF의 주요 재무 비율은 무엇인가요?
Novelstem International Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Gelion PLC의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Novelstem International Corp 주요 수익원은 North America이며, 최신 수익 발표에서 수익은 35,787,268,000입니다. 지역별로는 North America이 Novelstem International Corp의 주요 시장이며, 수익은 35,787,268,000입니다.
Gelion PLC은 수익성이 있나요?
no, 최신 재무제표에 따르면 Novelstem International Corp의 순손실은 $0입니다.